Psychosis, as a comorbidity, is seen in many neuropsychiatric and neurodegenerative disorders and is often treated with dopamine D2 receptor (D2R) antagonists, which could aggravate Alzheimer’s disease and Parkinson’s disease (PD) symptoms. Hence, there is a need for new treatments with a non-D2R antagonist-related mechanism of action. Recently approved drugs for psychosis in PD, including pimavanserin (PIM), and for schizophrenia, xanomeline-trospium, offer advances since they lack D2R antagonism but both carry associated risks. The highly-purified, plant-derived form of cannabidiol (hpCBD; Epidiolex®) has a different safety profile, does not inhibit D2R and has demonstrated antipsychotic effects in patients with psychosis.
Aims:
To systematically assess the potential antipsychotic-like effects of hpCBD, alongside newer non-D2 antagonist drugs approved for PD psychosis (PIM) and schizophrenia psychosis (xanomeline oxalate (XAN)) in the same set of standardised preclinical assays.
Methods:
MK-801-induced hyperlocomotion and pre-pulse inhibition (PPI) deficits in male C57BL/6J mice were assessed following PIM (0.1, 0.3, 1 mg/kg s.c.), XAN (1, 3, 10 mg/kg s.c.) or hpCBD (50, 100, 200 mg/kg i.p.) administration. Locomotor activity was measured by infrared photobeams and Laboratory Animal Behaviour Observation Registration and Analysis System, and PPI was measured in acoustic startle chambers using a variable pre-pulse intensity protocol.
Results:
PIM, XAN (all doses) and hpCBD (200 mg/kg) attenuated MK-801 hyperlocomotion (p < 0.01). PPI deficits, at various pre-pulse intensities, were attenuated by PIM (all doses), XAN 10 mg/kg and hpCBD 200 mg/kg (p < 0.05).
Conclusion:
These results suggest that hpCBD, like PIM and XAN, demonstrates putative antipsychotic-like activity in classic mouse assays relevant to psychosis, consistent with positive clinical data in patients with psychosis.
Abdul-RahmanTHerrera-CalderónREAderintoN, et al. (2024) Clearing the fog: A review of antipsychotics for Parkinson’s-related hallucinations: A focus on pimavanserin, quetiapine and clozapine. Journal of Integrative Neuroscience23(4): 80. https://doi.org/10.31083/j.jin2304080.
2.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Publishing.
3.
AndréRGomesAPPereira-LeiteC, et al. (2024) The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals17: 1543. https://doi.org/10.3390/ph17111543
BakshiVPSwerdlowNRBraffDL, et al. (1998) Reversal of isolation rearing-induced deficits in prepulse inhibition by seroquel and olanzapine. Biological Psychiatry43(6): 436–445. https://doi.org/10.1016/s0006-3223(97)00246-1
6.
BastTZhangWFeldonJ, et al. (2000) Effects of MK-801 and neuroleptics on prepulse inhibition: Re-examination in two strains of rats. Pharmacology Biochemistry and Behavior67(3): 647–58. https://doi.org/10.1016/s0091-3057(00)00409-3
7.
BehrensSGattazWF (1992) MK-801 induced stereotypies in rats are decreased by haloperidol and increased by diazepam. Journal of Neural Transmission. General Section90(3): 219–224. https://doi.org/10.1007/BF01250962
8.
BoggsDLSurtiTGuptaA, et al. (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology235: 192–1932. https://doi.org/10.1007/s00213-018-4885-9
9.
BraffDLGeyerMASwerdlowNR (2001) Human studies of prepulse inhibition of startle: Normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl)156(2–3): 234–258. https://doi.org/10.1007/s002130100810
CiliaJReavillCHaganJJ, et al. (2001) Long-term evaluation of isolation-rearing induced prepulse inhibition deficits in rats. Psychopharmacology156: 32–337. https://doi.org/10.1007/s002130100786
12.
CummingsJIsaacsonSMillsR, et al. (2014) Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet383(9916): 533–540. https://doi.org/10.1016/S0140-6736(13)62106-6
DaviesCBhattacharyyaS (2019) Cannabidiol as a potential treatment for psychosis. Therapeutic Advances in Psychopharmacology9: 1–16. https://doi.org/10.1177/2045125319881916
15.
De AlmeidaDLDeviLA (2020) Diversity of molecular targets and signaling pathways for CBD. Pharmacology Research & Perspectives8(6): e00682. https://doi.org/10.1002/prp2.682
16.
DeianaSWatanabeAYamasakiY, et al. (2012) Plasma and brain pharmacokinetic profile of cannabiodiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-complusive behaviour. Psychopharmacology219: 859–873. https://doi.org/10.1007/s00213-011-2415-0
17.
DevinskyOPatelADCrossJH, et al. (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. The New England Journal of Medicine378(20): 1888–1897. https://doi.org/10.1056/NEJMoa1714631
18.
DevinskyOJonesNACunninghamMO, et al. (2024) Cannabinoid treatments in epilepsy and seizure disorders. Physiological Reviews104: 591–649. https://doi.org/10.1152/physrev.00049.2021
19.
FactorSAMcDonaldWM (2016) Psychosis in Parkinson’s disease: Epidemiology, pathophysiology, and management. Journal of Parkinson’s Disease6(4): 735–748. https://doi.org/10.3233/JPD-160921
20.
FrankelJSSchwartzTL (2017) Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Therapeutic Advances in Psychopharmacology7(1): 29–41. https://doi.org/10.1177/2045125316672136
21.
GardellLRVanoverKEPoundsL, et al. (2007) ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. Journal of Pharmacology and Experimental Therapeutics322(2): 862–870https://doi.org/10.1124/jpet.107.121715
22.
Geter-DouglassBWitkinJM (1999) Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology (Berl)146(3): 280–289. https://doi.org/10.1007/s002130051118
23.
GeyerMAKrebs-ThomsonKBraffDL, et al. (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology156: 117–154. https://doi.org/10.1007/s002130100811
GrayRAWhalleyBJ (2020) The proposed mechanisms of action of CBD in epilepsy. Epileptic Disorders22(Suppl. 1): S10–S15. https://doi.org/10.1684/epd.2020.1135
26.
GururajanATaylorDAMaloneDT (2012) Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats. Journal of Psychopharmacology26(10): 1317–1332. https://doi.org/10.1177/0269881112441865
27.
HawkinsTBermanBD (2017) Pimavanserin: A novel therapeutic option for Parkinson disease psychosis. Neurology Clinical Practice7(2): 157–162. https://doi.org/10.1212/CPJ.0000000000000342
28.
IsaacsonSHBallardCGKreitzmanDL, et al. (2021) Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson’s disease psychosis patients. Parkinsonism and Related Disorders87: 25–31. https://doi.org/10.1016/j.parkreldis.2021.04.012
29.
IsonJRAllenPD (2003) Low-frequency tone pips elicit exaggerated startle reflexes in C57BL/6J mice with hearing loss. JARO4: 495–504. https://doi.org/10.1007/s10162-002-3046-2.
30.
JaehneEJVan den BuuseM (2019) The effect of cannabidiol on psychosis-like behaviour induced by methamphetamine and MK-801 in mice: A negative report. Journal of Psychiatry and Brain Science4: e190006. https://doi.org/10.20900/jpbs.20190006
KaulISawchakSCorrellCU, et al. (2024a) Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: Results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet403: 160–170. https://doi.org/10.1016/S0140-6736(23)02190-6
33.
KaulISawchakSWallingDP, et al. (2024b) Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A randomized clinical trial. JAMA Psychiatry81(8): 749–756. https://doi.org/10.1001/jamapsychiatry.2024.0785
34.
KnolWvan MarumRJJansenPA, et al. (2008) Antipsychotic drug use and risk of pneumonia in elderly people. Journal of the American Geriatrics Society56: 661–666. https://doi.org/10.1111/j.1532-5415.2007.01625.x
35.
LewekeFMPiomelliDPahlischF, et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry2: e94. https://doi.org/10.1038/tp.2012.15
36.
LoboMCWhitehurstTSKaarSJ, et al. (2022) New and emerging treatments for schizophrenia: A narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neuroscience and Biobehavioural Reviews132: 324–361. https://doi.org/10.1016/j.neubiorev.2021.11.032
37.
LongLEMaloneDTTaylorDA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology31: 795–803. https://doi.org/10.1038/sj.npp.1300838
38.
McFarlandKPriceDBonhausD (2011) Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson’s disease. Behavioural Pharmacology22(7): 681–692. https://doi.org/10.1097/FBP.0b013e32834aff98
39.
McGuirePRobsoPCubalaWJ, et al. (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. The American Journal of Psychiatry175(3): 225–231. https://doi.org/10.1176/appi.ajp.2017.17030325
40.
MeltzerHYMasseyBWHoriguchiM (2012) Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia. Current Pharmaceutical Biotechnology13(8): 1572–1586. https://doi.org/10.2174/138920112800784880
41.
MillarSAStoneNLBellmanZD, et al. (2019) A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology85(9): 1888–1900. https://doi.org/10.1111/bcp.14038
42.
MinassianAYoungJWCopeZA, et al. (2016) Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology (Berl)233(2): 225–233. https://doi.org/10.1007/s00213-015-4098-4
43.
MontaniCCanellaCSchwarzAJ, et al. (2021) The M1/M4 prefering muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. Neuropsychopharmacology46: 1194–1206. https://doi.org/10.1038/s41386-020-00916-0
44.
MoreiraFAGuimarãesFS (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. European Journal of Pharmacology512: 199–205. https://doi.org/10.1016/j.ejphar.2005.02.040
45.
National Research Council (2011) Guide for the Care and Use of Laboratory Animals, 8th edn. Washington, DC: National Academies Press.doi:10.17226/12910
46.
NoelC (2017) Evidence for the use of “medical marijuana” in psychiatric and neurologic disorders. Mental Health Clinician7(1): 29–38. https://doi.org/10.9740/mhc.2017.01.029
47.
O’NeillMFShawG (1999) Comparison of dopamine receptor antagonists on hyperlocomotion induced by cocaine, amphetamine, MK-801 and the dopamine D1 agonist C-APB in mice. Psychopharmacology (Berl)145(3): 237–250. https://doi.org/10.1007/s002130051055
48.
PaylorRCrawleyJN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology132(2): 169–180. https://doi.org/10.1007/s002130050333
49.
PedrazziJFCSalesAJGuimarãesFS, et al. (2021) Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. Progress in Neuropsychopharmacology and Biological Psychiatry111: 110352. https://doi.org/10.1016/j.pnpbp.2021.110352
50.
PedrazziJFCSilva-AmaralDIssyAC, et al. (2024) Cannabidiol attenuates prepulse inhibition disruption by facilitating TRPV1 and 5-HT1A receptor-mediated neurotransmittion. Pharmacology, Biochemistry and Behavior245: 173879. https://doi.org/10.1016/j.pbb.2024.173879
51.
QuinnLPSteanTOTrailB, et al. (2003) LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour. Journal of Neuroscience Methods130(1): 83–92. https://doi.org/10.1016/S0165-0270(03)00227-9
52.
RalphRJVartyGBKellyMA, et al. (1999) The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. The Journal of Neuroscience19(11): 4627–4633. https://doi.org/10.1523/JNEUROSCI.19-11-04627.1999
53.
RanaRRRajasekaranKKnappertzV, et al. (2023) Pharmacodynamic synergism contributes to the antiseizure action of cannabidiol and clobazam. Experimental Neurology360: 114286. https://doi.org/10.1016/j.expneurol.2022.114286
54.
RussoEB (2011) Taming THC: Potential cannabis synergy and phytocannabiniod-terpenoid entourage effects. The British Journal of Pharmacology163: 1344–1364. https://doi.org/10.1111/j.1476-5381.2011.01238.x
55.
Santos-CarrascoDCasa De laLG (2023) Prepulse inhibition deficits as transdiagnostic process in neuropsychiatric disorders: a systematic review. BMC Psychology11: 226. https://doi.org/10.1186/s40359-01253-9
56.
SchotteAJanssenPFGommerenW, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl)124(1–2): 57–73. https://doi.org/10.1007/BF02245606
57.
SeemanP (2016) Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry6: e920. https://doi.org/10.1038/tp.2016.195
58.
ShojiHMiyakawaT (2018) Relationships between the acoustic startle response and prepulse inhibition in C57BL/6J mice: A large-scale meta-analytic study. Molecular Brain11: 42. https://doi.org/10.1186/s13041-018-0382-7
59.
SteinbergMLyketsosCG (2012) Atypical antipsychotic use in patients with demetia: Managing safety concerns. The American Journal of Psychiatry169(9): 900–906. https://doi.org/10.1176/appi.ajp.2012.12030342
60.
SuYSiTZhouD, et al. (2007) Risperidone attenuates MK-801-induced hyperlocomotion in mice via the blockade of serotonin 5-HT2A/2C receptors. European Journal of Pharmacology564(1–3): 123–130. https://doi.org/10.1016/j.ejphar.2007.02.031
61.
TariotPNCummingsJLSoto-MartinME, et al. (2021) Trial of pimavanserin in dementia-related psychosis. The New England Journal of Medicine385(4): 309–319. https://doi.org/10.1056/NEJMoa2034634
62.
TiedtkePIBischoffCSchmidtWJ (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. Journal of Neural Transmission. General Section 1990; 81(3): 173–182. https://doi.org/10.1007/BF01245040
63.
ThieleEAMarshEDFrenchJA, et al. (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet391(10125): 1085–1096. https://doi.org/10.1016/S0140-6736(18)30136-3
64.
ThieleEABebinEMBhathalH, et al. (2021) Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial. JAMA Neurology78(3): 285–292. https://doi.org/10.1001/jamaneurol.2020.4607
65.
TricklebankMDSinghLOlesRJ, et al. (1989) The behavioural effects of MK-801: A comparison with antagonists acting non-competitively and competitively at the NMDA receptor. European Journal of Pharmacology167(1): 127–135. https://doi.org/10.1016/0014-2999(89)90754-1
66.
van den BuuseM (2010) Modeling the positive symptoms of schizophrenia in genetically modified mice: Pharmacology and methodology aspects. Schizophrenia Bulletin36(2): 246–270. https://doi.org/10.1093/schbul/sbp132
67.
VanoverKEWeinerDMMakhayM, et al. (2006) Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. Journal of Pharmacology and Experimental Therapeutics317(2): 910–918. https://doi.org/10.1124/jpet.105.097006
68.
VartyGBHigginsGA (1995) Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology (Berl.)122(1): 15–26. https://doi.org/10.1007/BF02246437
69.
VartyGBWaltersNCohen-WilliamsM, et al. (2001) Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. European Journal of Pharmacology424: 27–36. https://doi.org/10.1016/s0014-2999(01)01115-3
70.
WuJZouHStrongJA, et al. (2005) Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology (Berl.)177(3): 256–263. https://doi.org/10.1007/s00213-004-1944-1
71.
WillottJFCarlsonSChenH (1993) Plasticity of auditory cortex associated with sensineural hearing loss in adult C57BL/6J mice. The Journal of Comparative Neurology329: 402–411. https://doi.org/10.1002/cne.903290310
72.
YoungJWWallaceCKGeyerMA, et al. (2010) Age-associated improvements in cross-modal prepulse inhibition in mice. Behavioral Neuroscience124(1): 133–140. https://doi.org/10.1037/a0018462
73.
ZuardiAWShirakawaIFinkelfarbE, et al. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychpharmacology (Berl.)76(3): 245–250. https://doi.org/10.1007/BF00432554
74.
ZuardiAWCrippaJASHallakJEC, et al. (2009) Cannabidiol for the treatment of psychosis in Parkinson’s disease. The Journal of Psychopharmacology23(8): 979–983. https://doi.org/10.1177/0269881108096519
75.
ZuardiAWCrippaJASHallakJEC, et al. (2012) A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design18: 5131–5140. https://doi.org/10.2174/138161212802884681
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
